These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7913498)

  • 1. Aquaretic effect of the stable dynorphin-A analog E2078 in the human.
    Ohnishi A; Mihara M; Yasuda S; Tomono Y; Hasegawa J; Tanaka T
    J Pharmacol Exp Ther; 1994 Jul; 270(1):342-7. PubMed ID: 7913498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.
    Ohnishi A; Orita Y; Okahara R; Fujihara H; Inoue T; Yamamura Y; Yabuuchi Y; Tanaka T
    J Clin Invest; 1993 Dec; 92(6):2653-9. PubMed ID: 8254021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
    Ohnishi A; Orita Y; Takagi N; Fujita T; Toyoki T; Ihara Y; Yamamura Y; Inoue T; Tanaka T
    J Pharmacol Exp Ther; 1995 Feb; 272(2):546-51. PubMed ID: 7853167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of the dynorphin derivative "E2078" on hemodynamics and plasma catecholamines in dogs].
    Hirota K
    Masui; 1990 Jul; 39(7):890-9. PubMed ID: 1976830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [N-methyl-Tyr1,N-methyl-Arg7-D-Leu8]-dynorphin-A-(1-8)ethylamide, a stable dynorphin analog, produces diuresis by kappa-opiate receptor activation in the rat.
    Salas SP; Roblero JS; López LF; Tachibana S; Huidobro-Toro JP
    J Pharmacol Exp Ther; 1992 Sep; 262(3):979-86. PubMed ID: 1356155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites.
    Guyader D; Patat A; Ellis-Grosse EJ; Orczyk GP
    Hepatology; 2002 Nov; 36(5):1197-205. PubMed ID: 12395330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analgesic efficacy of E2078 (dynorphin analog) in patients following abdominal surgery].
    Fujimoto K; Momose T
    Masui; 1995 Sep; 44(9):1233-7. PubMed ID: 8523656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis.
    Inoue T; Ohnishi A; Matsuo A; Kawai B; Kunihiro N; Tada Y; Koizumi F; Chau T; Okada K; Yamamura Y; Tanaka T
    Clin Pharmacol Ther; 1998 May; 63(5):561-70. PubMed ID: 9630829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative modulation of nitric oxide production by neurotensin as a putative mechanism of the diuretic action of SR 48692 in rats.
    Croci T; Landi M; Gully D; Maffrand JP; Le Fur G; Manara L
    Br J Pharmacol; 1997 Apr; 120(7):1312-8. PubMed ID: 9105707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of E2078, a new dynorphin derivative, on pituitary-adrenocortical functions in dogs].
    Muraoka M
    Masui; 1990 Jul; 39(7):900-9. PubMed ID: 1976831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients.
    Abraham WT; Shamshirsaz AA; McFann K; Oren RM; Schrier RW
    J Am Coll Cardiol; 2006 Apr; 47(8):1615-21. PubMed ID: 16630999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention.
    Bosch-Marcé M; Poo JL; Jiménez W; Bordas N; Leivas A; Morales-Ruiz M; Muñoz RM; Pérez M; Arroyo V; Rivera F; Rodés J
    J Pharmacol Exp Ther; 1999 Apr; 289(1):194-201. PubMed ID: 10087004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diuretic actions in man of a selective kappa opioid agonist: U-62,066E.
    Peters GR; Ward NJ; Antal EG; Lai PY; deMaar EW
    J Pharmacol Exp Ther; 1987 Jan; 240(1):128-31. PubMed ID: 3027300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study.
    Thuluvath PJ; Maheshwari A; Wong F; Yoo HW; Schrier RW; Parikh C; Steare S; Korula J
    Aliment Pharmacol Ther; 2006 Sep; 24(6):973-82. PubMed ID: 16948809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985.
    Decaux G
    J Lab Clin Med; 2001 Jul; 138(1):18-21. PubMed ID: 11433224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
    Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
    Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic and regional hemodynamic and biological effects of a new kappa-opioid agonist, niravoline, in healthy volunteers.
    Bellissant E; Denolle T; Sinnassamy P; Bichet DG; Giudicelli JF; Lecoz F; Gandon JM; Allain H
    J Pharmacol Exp Ther; 1996 Jul; 278(1):232-42. PubMed ID: 8764356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats.
    Hirano T; Yamamura Y; Nakamura S; Onogawa T; Mori T
    J Pharmacol Exp Ther; 2000 Jan; 292(1):288-94. PubMed ID: 10604960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery.
    Schroth M; Plank C; Meissner U; Eberle KP; Weyand M; Cesnjevar R; Dötsch J; Rascher W
    Pediatrics; 2006 Jul; 118(1):e76-84. PubMed ID: 16751617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerance to subchronic, high-dose ingestion of erythritol in human volunteers.
    Tetzloff W; Dauchy F; Medimagh S; Carr D; Bär A
    Regul Toxicol Pharmacol; 1996 Oct; 24(2 Pt 2):S286-95. PubMed ID: 8933645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.